Magdalena Beata Skarzynska

Dr. Magdalena Beata Skarzynska

Institute of Sensory Organs, Kajetany 05-830, Poland
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2018 in Medical Science Monitor
Verified
Journal Article
Closed access
PDF file
Magdalena Beata SkarzynskaMagdalena Beata Skarzynska
Magdalena Beata Skarzynska
Piotr H. SkarzynskiPiotr H. Skarzynski
Piotr H. Skarzynski
BKBartłomiej Król
Bartłomiej Król
MKMagdalena Kozieł
Magdalena Kozieł
KOKamila Osińska
Kamila Osińska
Henryk SkarzynskiHenryk Skarzynski
Henryk Skarzynski
BACKGROUND:A prospective clinical study was conducted to assess different regimens of steroid therapy and preservation of hearing following cochlear implantation. MATERIAL AND METHODS:Study participants were ≥18 years-of-age, with a cochlear duct l...

12 July 2016 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
Piotr H. SkarzynskiPiotr H. Skarzynski
Piotr H. Skarzynski
WŚWeronica Świerniak
Weronica Świerniak
APAdam Piłka
Adam Piłka
Magdalena Beata SkarzynskaMagdalena Beata Skarzynska
Magdalena Beata Skarzynska
AWAndrzej W. Włodarczyk
Andrzej W. Włodarczyk
SHStavros Hatzopoulos
Stavros Hatzopoulos
BACKGROUND:According to the guidelines of the European Scientific Consensus on Hearing (European Federation of Audiology Societies ‘EFAS’ Congress, June 2011, Warsaw, Poland), the detection and treatment of communication disorders in early school...

10 January 2022 in Life
Verified
Journal Article
Open access
PDF file
Magdalena Beata SkarzynskaMagdalena Beata Skarzynska
Magdalena Beata Skarzynska
ACAleksandra Chodkiewicz
Aleksandra Chodkiewicz
EGElżbieta Gos
Elżbieta Gos
MSMilaine Dominici Sanfis
Milaine Dominici Sanfis
Piotr H. SkarzynskiPiotr H. Skarzynski
Piotr H. Skarzynski
(1) Background: A retrospective clinical study was conducted to compare the effectiveness of different pharmacological and non-pharmacological regimens for treating sudden sensorineural hearing loss (SSNHL). (2) Methods: Adult patients (n = 130) diagnosed with sudden sensorineural hearing loss (SSNHL) and hospitalized between 2015 and 2020 were enrolled in this study. Depending on the treatment regimen applied, patients were divided into five groups. Inclusion criteria were as follows: (i) hearing loss of sudden onset; (ii) hearing loss of at least 30 dB at three consecutive frequencies; (iii) unilateral hearing loss; (iv) age above 18 years. Exclusion criteria were as follows: (i) no follow-up audiogram; (ii) bilateral hearing loss; (iii) recognized alternative diagnosis such as tumor, disorder of inner ear fluids, infection or inflammation, autoimmune disease, malformation, hematological disease, dialysis-dependent renal failure, postdural puncture syndrome, gene-related syndrome, mitochondrial disease; and (iv) age below 18 years. (3) Results: Complete recovery was found in 14% of patients (18/130) and marked improvement was found in 6% (8/130), giving an overall success rate of 20%. The best results were obtained in the second group (i.e., patients given intratympanic glucocorticoid + prolonged orally administered glucocorticoid) where the success rate was 28%. In general, the older the patient, the smaller the improvement in hearing, a correlation that was statistically significant. (4) Conclusions: In treating SSNHL, the highest rate of hearing recovery—28%—was in the group of patients given intratympanic corticoid plus prolonged treatment with orally administered glucocorticoid.

31 December 2014 in Journal of Hearing Science
Verified
Journal Article
Closed access
Piotr H. SkarzynskiPiotr H. Skarzynski
Piotr H. Skarzynski
APAdam Piłka
Adam Piłka
MLMaciej Ludwikowski
Maciej Ludwikowski
Magdalena Beata SkarzynskaMagdalena Beata Skarzynska
Magdalena Beata Skarzynska
Objective: Universal newborn hearing screening programs have been successfully implemented in many countries, and result in early intervention and therapy. However, there are also a significant number of schoolchildren who have hearing problems. This study presents the results of a program of hearing screening in schoolchildren, implemented in Poland and subsequently followed up in other countries in support of the European Consensus on school-age hearing screening. The aim was to compare the frequency of positive outcomes of hearing screening between the countries.Material and Methods: Screening outcomes from the following countries were compared: Poland, Moldova, Romania, Russia, Tajikistan, Kyrgyzstan, Azerbaijan, Armenia, Senegal, and the Ivory Coast. Screening was performed using the Sense Examination Platform, developed in Warsaw, Poland, by the Institute of Sensory Organs and the Institute of Physiology and Pathology of Hearing. The Platform comprises a central computer and a number of other portable computers communicating with the central database via the Internet, and can perform pure tone audiometry and other hearing, speech, and vision tests. It also records the answers to an audiological questionnaire. The test was considered to be positive when pure tone audiometry was higher than 20 dB HL for at least one frequency.Results: Among children aged 6–8 years from Poland the rate of positive results was 13.9%, while in children aged 12–15 years it was 8.5%. From the other European countries in which 462 children were tested, positive results occurred in 62 (13.4%). In four countries of Central Asia, positive outcomes of hearing screening were found in 216 children from 1011 tested (21.4%). In two African countries, positive results were found in 105 children from 321 tested (32.7%). The questionnaire surveys have shown that more than 30% of children with normal hearing have tinnitus, and the figure rises to nearly 50% in children with an abnormal result. Only 33% of children with hearing problems reported them to parents. In Poland, only 40% of children with hearing loss are under the care of a specialist, compared with only about half that number in children from Tajikistan and Moldova.Conclusions: This study demonstrates that there are many children in primary schools who have hearing problems, and this situation may affect their education. The solution could be screening programs conducted directly in schools by trained school personnel (e.g. school nurses). The program of hearing screening in schoolchildren described here has helped to raise awareness of the importance of hearing conservation and inspired the development of new programs.

22 September 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Magdalena Beata SkarzynskaMagdalena Beata Skarzynska
Magdalena Beata Skarzynska
ACAleksandra Chodkiewicz
Aleksandra Chodkiewicz
EGElżbieta Gos
Elżbieta Gos
AWAdam Walkowiak
Adam Walkowiak
ALArtur Lorens
Artur Lorens
Piotr H. SkarzynskiPiotr H. Skarzynski
Piotr H. Skarzynski
The main aim of this study was to assess the clinical effect of steroids (dexamethasone and prednisone) on hearing preservation in patients who underwent cochlear implantation with different cochlear implant systems (Oticon®, Advanced Bionics®, Med-El®). 147 adult patients met the inclusion criteria and were enrolled to the study and divided into three groups depending on the brand of cochlear implant they received and participated in all follow-up visits regularly. They were also randomly divided into three subgroups depending on the steroid administration regime: (1) intravenous dexamethasone (0.1 mg/kg body weight twice a day for three days); (2) combined intravenous and oral steroids (dexamethasone 0.1 mg/kg body weight twice a day plus prednisone 1 mg/kg weight once a day); and (3) no steroids (control group). The results were measured by pure tone audiometry (PTA) at three time points: (i) before implantation, (ii) at processor activation, and (iii) 12 months after activation. A hearing preservation (HP) figure was also calculated by comparing the preoperative results and the results after 12 months. Further measures collected were electrode impedance and hearing threshold in the non-operated ear. The highest HP measures (partial and complete) were obtained in the subgroups who were given steroids. Of the 102 patients given steroids, HP was partial or complete in 63 of them (62%). In comparison, partial or complete HP was achieved in only 15 patients out of 45 (33%) who were not given steroids. There were differences between the three cochlear implant groups, with the Med-El and Advanced Bionics groups performing better than the Oticon group (45% and 43% of the former two groups achieved partial or complete HP compared to 20% in the latter). Hearing thresholds in the non-operated ear were stable over 12 months. Generally, impedance was slightly lower in the 12 month follow-up in comparison with the activation period, with the exception of the Oticon group. (4) Conclusions: Pharmacological treatment with steroids in patients undergoing cochlear implantation helps to preserve residual hearing.

29 April 2022 in Audiology Research
Verified
Journal Article
Open access
PDF file
Magdalena Beata SkarzynskaMagdalena Beata Skarzynska
Magdalena Beata Skarzynska
MMMonika Matusiak
Monika Matusiak
Piotr H. SkarzynskiPiotr H. Skarzynski
Piotr H. Skarzynski
(1) Background: The purpose of this article is to review pharmacological treatments for COVID-19 (currently approved by the EMA (European Medical Agency) and FDA (Food and Drug Administration)) and highlight their potential audio-vestibular side-effects as an ototoxic adverse reaction. (2) Methods: Review of the available literature in the scientific databases PubMed, ResearchGate, Scopus, and ScienceDirect, and in summaries of product data sheets. (3) Results: In accordance with EBM (evidence-based medicine) the treatment of COVID-19 by using lopinavir/ritonavir, chloroquine and hydroxychloroquine, azithromycin, favipiravir, amantadine, oseltamivir, and ivermectin is no longer recommended for patients suffering from COVID-19 due to a lack of clinical data, publications, and recommendations. There were 39 publications and 15 summaries of product characteristics (as other sources of data) which were also used in this analysis. Adverse events could be permanent or disappear over time. Following treatment for COVID-19, the most frequent adverse audio-vestibular reactions reported in clinical trials and publications in the area of audiology and otorhinolaryngology were: dizziness, blurry vision with dizziness, nasopharyngitis, dysgeusia, and tinnitus. As far as vaccines are concerned, dizziness as an ototoxic effect was uncommon and occurs only in hypersensitive people who experience anaphylactic shock. (4) Conclusions: The ototoxicity of the drugs discussed here does not have as severe symptoms as the drugs used in the treatment of COVID-19 in 2020 (e.g., hydroxychloroquine), and relates mainly to disorders of the vestibulocochlear system. However, there is still a need to monitor ototoxic side-effects because of potential interactions with other ototoxic drugs. Many of the drugs approved by EMA and FDA are new, and not every side-effect is known.